NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

NCT02803918

CompletedPhase 1

Sponsor: Sanofi

Conditions: Type 2 Diabetes Mellitus

Interventions: Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin

Countries: United States, Mauritius, Mexico, South Africa, Spain, Turkey (Türkiye)

Primary Objective: To demonstrate safety of 14-day repeated lixisenatide doses with 3 ascending doses as compared to placebo in pediatric patients with T2DM. Secondary Objectives: * To evaluate plasma concentrations of lixisenatide after repeated doses (3 ascending doses) and pharmacokinetic parameters of repeated lixisenatide doses in pediatric patients with T2DM. * To evaluate the change from baseline in fasting and post-prandial plasma glucose concentrations during a standardized meal test after 3 ascending repeated doses of lixisenatide in comparison to placebo.

Eligibility overview

Sex: ALL

Age: 10 Years to 17 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion criteria :

* Male or female patients aged ≥10 and \<18 years old (at least 4 patients below 16 years old).
* Body mass index (BMI) \>85th percentile for age and gender; BMI ≤50 kg/m2.
* Male and female patients with documented T2DM insufficiently controlled with metformin at a stable dose and regimen for 8 weeks prior to randomization and/or basal insulin at stable dose (± 20%) and regimen for 8 weeks prior to randomization. The exact individual metformin dose will be selected according to local regulation and to the investigator's medical judgment.
* Glycated hemoglobin (HbA1c) \>6.5% and ≤11% at screening.

Exclusion criteria:

* If female, ongoing pregnancy (defined as positive serum pregnancy test), breast-feeding.
* Sexually active postmenarchal female patient who does not agree to use an adequate and highly effective method of contraception throughout the study duration and according to local regulation (ie, hormonal contraception, condom, etc.).
* Diabetes other than T2DM.
* Fasting plasma glucose \>250 mg/dL (\>13.9 mmol/L) at screening.
* Use of other oral or injectable antidiabetic or hypoglycemic agents other than metformin and basal insulin (eg, alpha glucosidase inhibitor, glucagon-like peptide (GLP-1) receptor agonist, dipeptidyl peptidase-IV (DPP-IV) inhibitors, short-acting insulin etc.) within 1 month prior to the screening visit.
* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (11)

Baton Rouge, Louisiana, United States
New Orleans, Louisiana, United States
Philadelphia, Pennsylvania, United States
Lufkin, Texas, United States
Phoenix, Mauritius
Monterrey, Mexico
Puebla City, Mexico
Cape Town, South Africa
Barcelona, Spain
Ankara, Turkey (Türkiye)
Izmir, Turkey (Türkiye)